Skip to main content

Table 1 Clinical characteristics from CIDP patients with INCAT disability score, MRC sum score, and treatment history

From: Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins

Patient Sex Age Treatment before sampling IVIg treatment duration before d1 (months) INCAT score d1 INCAT score 6 months MRC SS d1 MRC SS 6 months Dimer content pre-IVIg d1 (%) Dimer content post-IVIg d1 (%)
1 M 58 CS 0 2 2 58 58 1.3 3.0
2 M 62 CS, IVIg 9 2 2 58 58 3.8 11.3
3 M 67 CS, IVIg 16 1 2 60 60 5.4 5.5
4 M 34 CS, IVIg 10 1 2 52 52 2.4 2.4
5 F 79 CS, IVIg 28 7 6 52 52 4.6 9.3
6 M 61 IVIg 16 2 2 58 58 1.8 4.2
7 M 74 CS, IVIg 27 7 7 46 46 3.7 11.3
8 F 69 IVIg 5 0 0 60 60 2.7 6.0
9 F 73 CS, CP 6 4 7 52 47 2.3 4.1
10 M 48 CS, IVIg 6 3 1 58 58 2.1 3.4
11 F 56 IVIg 2 3 3 58 58 2.1 2.3
12 F 71 IVIg 8 0 0 60 60 3.9 7.4
13 F 79 IVIg 10 2 2 52 52 1,9 7,7
14 M 65 IVIg 10 2 2 58 58 0 4.2
15 F 78 CS, IVIg 12 1 1 58 58 3.7 6.2
16 M 57 - 0 2 2 60 60 0 3.9
  1. CS cortisone, CP cyclophosphamide, SS sum score